Neville Rodie & Shaw Inc Bio Line Rx Ltd. Transaction History
Neville Rodie & Shaw Inc
- $1.37 Billion
- Q4 2024
A detailed history of Neville Rodie & Shaw Inc transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Neville Rodie & Shaw Inc holds 10,000 shares of BLRX stock, worth $1,200. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$1,200% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BLRX
# of Institutions
40Shares Held
3.38MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$103,9790.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$97,8814.05% of portfolio
-
Envestnet Asset Management Inc239KShares$28,7020.0% of portfolio
-
Morgan Stanley New York, NY198KShares$23,7040.0% of portfolio
-
Values First Advisors, Inc.198KShares$23,7010.06% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $7.38M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...